Current treatment strategies in ANCA-positive renal vasculitis-lessons from European randomized trials.
Nephrol Dial Transplant
; 18 Suppl 5: v2-4, 2003 Jul.
Article
en En
| MEDLINE
| ID: mdl-12817056
Antineutrophil cytoplasmic antibody (ANCA)-positive renal vasculitis is the most common cause of rapidly progressive (crescentic) glomerulonephritis. Its life-threatening natural course may be modified substantially by current treatment modalities. The European Vasculitis Study Group (EUVAS) developed a subclassification of ANCA-positive vasculitides based on the disease severity at presentation, and have organized (so far) two waves of clinical trials. The first wave of randomized clinical trials had the aim of optimizing the existing therapeutic regimens; the second wave concentrated on testing some newer therapeutic approaches. Here, the design and available results of the first wave and the design of some second wave trials are reviewed briefly. The potential of the new targeted approaches (e.g. anti-tumour necrosis factor therapy) is also briefly mentioned.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Vasculitis
/
Plasmaféresis
/
Anticuerpos Anticitoplasma de Neutrófilos
/
Glomerulonefritis
/
Inmunosupresores
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
/
Prognostic_studies
Límite:
Female
/
Humans
/
Male
País/Región como asunto:
Europa
Idioma:
En
Revista:
Nephrol Dial Transplant
Asunto de la revista:
NEFROLOGIA
/
TRANSPLANTE
Año:
2003
Tipo del documento:
Article
País de afiliación:
República Checa
Pais de publicación:
Reino Unido